BC patients showed the highest prevalence of EGFR mutations (21%) followed by KRAS (11.4%), whereas in ON and QC patients, KRAS mutations were observed more frequently relative to EGFR (Table 4, Figure 2). Here, EGFR is linked to breast cancer.